Changes after publication
March 2014: minor maintenance
March 2012: minor maintenance
March 2010: This guidance has been partially updated by 'Unstable angina and NSTEMI' (NICE clinical guideline 94).
The Institute reviews each piece of guidance it issues. The review and re-appraisal of the glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (ACS) has resulted in a revision of the definition of high-risk patients in relation to the use of these agents in initial medical management of ACS, and in a clarification of the recommendation on the use of a glycoprotein IIb/IIIa inhibitor as an adjunct to percutaneous coronary intervention.